[{"orgOrder":0,"company":"Panacela Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Panacela Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacela Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Panacela Labs \/ Undisclosed"},{"orgOrder":0,"company":"Panacela Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Panacela Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Panacela Labs \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Panacela Labs \/ Undisclosed"},{"orgOrder":0,"company":"Ipca Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Ipca Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ipca Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ipca Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Zydus Lifesciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Rundo International Pharmaceutical Research & Development","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Rundo International Pharmaceutical Research & Development","highestDevelopmentStatusID":"11","companyTruncated":"GSK \/ Rundo International Pharmaceutical Research & Development"},{"orgOrder":0,"company":"University of Manitoba","sponsor":"St. Boniface Hospital | Health Sciences Centre Winnipeg | University at Buffalo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University of Manitoba","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Manitoba \/ St. Boniface Hospital | Health Sciences Centre Winnipeg | University at Buffalo","highestDevelopmentStatusID":"8","companyTruncated":"University of Manitoba \/ St. Boniface Hospital | Health Sciences Centre Winnipeg | University at Buffalo"},{"orgOrder":0,"company":"Iroko Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Iroko Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Iroko Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iroko Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Iroko Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Iroko Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Iroko Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iroko Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Iroko Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase III","graph3":"Iroko Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Iroko Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Iroko Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Indomethacin","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Ntn Buzztime","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Cyclophosphamide","moa":"||Cytokine receptor unspecific (CRF)","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Ntn Buzztime","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Ntn Buzztime"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Cytokine receptor unspecific (CRF)","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Duke University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ Duke University School of Medicine"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"KVK.Tech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Ketotifen Fumarate","moa":"||Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sen-Jam Pharmaceutical \/ KVK.Tech","highestDevelopmentStatusID":"10","companyTruncated":"Sen-Jam Pharmaceutical \/ KVK.Tech"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Kingswood Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Financing","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Kingswood Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Kingswood Capital Markets"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Spartan Capital Securities"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Thinkequity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Thinkequity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Thinkequity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Interleukin 2","moa":"||Interleukin 2 receptor beta (IL2RB)||Interleukin-2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Arthrexin
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
